PBPK-based translation from preclinical species to humans for the full-size IgG therapeutic efalizumab

Authors: Maria Franz, Ravi Kumar Jairam, Lars Kuepfer, Nina Hanke

Source: Frontiers in Pharmacology, Vol 15 (2024)

Subject Terms: efalizumab, raptiva, cross-species translation, physiologically based pharmacokinetic modeling (PBPK), monoclonal antibody (mAb), target mediated drug disposition (TMDD), Therapeutics. Pharmacology, RM1-950

File Description: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fphar.2024.1418870/full; https://doaj.org/toc/1663-9812

Access URL: https://doaj.org/article/584054ca9bd24dc6b481a8570bbae847

Cardio-metabolic co-morbidities and psoriasis
Raptiva; une efficacite demontree sur 3 ans, symposium EADV; a trusted therapy for enduring disease reduction of psoriasis, symposium EADV

Authors: Gulliver, W.P.

Source: ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE. 135(Supp/6):S301-S306

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCCN071328090&indx=1&recIds=ETOCCN071328090

Pharmacogenomics: getting closer to a tailored therapy?
Raptiva; une efficacite demontree sur 3 ans, symposium EADV; a trusted therapy for enduring disease reduction of psoriasis, symposium EADV

Authors: Costanzo, A.

Source: ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE. 135(Supp/6):S311-S315

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCCN071328117&indx=1&recIds=ETOCCN071328117

Psoriasis as a chronic inflammatory syndrome
Raptiva; une efficacite demontree sur 3 ans, symposium EADV; a trusted therapy for enduring disease reduction of psoriasis, symposium EADV

Authors: Jullien, D.

Source: ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE. 135(Supp/6):S296-S300

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCCN071328087&indx=1&recIds=ETOCCN071328087

Results of three years 2243 and CONTROL Il with efalizumab clinical trials
Raptiva; une efficacite demontree sur 3 ans, symposium EADV; a trusted therapy for enduring disease reduction of psoriasis, symposium EADV

Authors: Bagot, M.

Source: ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE. 135(Supp/6):S307-S310

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCCN071328100&indx=1&recIds=ETOCCN071328100

Psoriasis drug withdrawn from market

Source: The Canadian Broadcasting Corporation (CBC). June 17, 2009

Psoriasis Drug To Be Removed

Source: The New York Times. April 9, 2009, Vol. 158 Issue 54640, pB12.

Raptiva Withdrawal Offers Upside for Enbrel and Humira According to Latest BioTrends Survey of U.S. Dermatologists

Source: PR Newswire. May 28, 2009

Latest BioTrends Research Reports to Assess the Impact of the Withdrawal of Raptiva (efalizumab) on the Psoriasis Market

Source: PR Newswire. April 10, 2009

Raptiva is withdrawn from the U.S. market

Source: UPI NewsTrack. April 9, 2009

FDA: Psoriasis drug causes some deaths

Source: UPI NewsTrack. February 19, 2009

Genentech Announces Positive Results from a Phase IV Study of Raptiva in Patients With Moderate-to-Severe Hand and Foot Psoriasis.

Source: PR Newswire. February 2, 2007

Seronons 2005 Adjusted(i) EPS Increased by 34.6%.

Source: PR Newswire. February 6, 2006

MANUFACTURERS SAY ARTHRITIS DRUG FAILS IN EXPERIMENT.

Source: The New York Times. May 13, 2003 C4.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

Labeling updates and warnings through November 2008 for efalizumab (Raptiva)

Source: Formulary (USA), November 1, 2008 Medication Safety and Reliability, 3pp

Labeling updates and warnings through December 2008 for efalizumab and bisphosphonates

Source: Formulary (USA), December 1, 2008 Medication Safety and Reliability, 4pp

Labeling updates and warnings through March 2009 for zonisamide and efalizumab

Authors: By:Formulary journal staff

Source: Formulary (USA), March 1, 2009 Medication Safety and Reliability, 4pp